| Literature DB >> 22533971 |
Alfredo Mayor1, Elisa Serra-Casas, Eduard Rovira-Vallbona, Alfons Jiménez, Llorenç Quintó, Betuel Sigaúque, Carlota Dobaño, Azucena Bardají, Pedro L Alonso, Clara Menéndez.
Abstract
BACKGROUND: The risk of Plasmodium falciparum malaria increases during pregnancy and at early postpartum. Immunological and physiological alterations associated with pregnancy that persist after delivery may contribute to the susceptibility to P. falciparum during early postpartum period.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22533971 PMCID: PMC3423004 DOI: 10.1186/1475-2875-11-130
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
IgG levels against the surface of erythrocytes infected with the parasite lines CS2 and MOZ2, by infection at postpartum
| | | | ||||
|---|---|---|---|---|---|---|
| | 78.9 | 28.4-305.9 | 526.9 | 163.4-766.1 | ||
| | 45.8 | 23.8-83.6 | 83.3 | 49.2-127.6 | ||
| | 47.4 | 22.4-184.5 | 53.3 | 39.2-104.5 | 0.845 | |
| 36.4 | 19.3-62.4 | 44.6 | 17.6-52.0 | 0.991 | ||
IQR: Inter-quartile range.
* Analysis excluding women with placental malaria to rule out the boosting of antibodies by infection at delivery.
Number of women with a positive or negative difference in IgG levels between postpartum and delivery, and magnitude of the difference
| | | | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| | | | ||||||||
| | | | | | | | | |||
| | | 115 | 85 | 5.8 | 0.054 | 57 | 38 | 6.1 | ||
| | | 120 | 80 | 9.8 | 56 | 39 | 10.0 | |||
| | | | | | | | | | ||
| | | | | | | | | |||
| | | 24 | 26 | 4.7 | 0.828 | 9 | 9 | −1.4 | 0.557 | |
| | | 31 | 19 | 8.3 | 0.121 | 12 | 6 | 21.3 | 0.349 | |
| | | | | | | | | |||
| | | 20 | 17 | 0.8 | 0.886 | 9 | 7 | 3.5 | 0.351 | |
| | | 21 | 16 | 6.7 | 0.213 | 7 | 9 | −0.1 | 0.569 | |
| | | | | | | | | |||
| | | 71 | 42 | 13.9 | 39 | 22 | 18.4 | |||
| | | 68 | 45 | 10.4 | 37 | 24 | 10.0 | 0.054 | ||
| | | | | | | | ||||
| | | | | | | | | | ||
| | | 24 | 15 | 19.1 | 0.116 | 9 | 10 | −3.5 | 0.904 | |
| | | 22 | 17 | 17.7 | 0.357 | 8 | 11 | −0.1 | 0.658 | |
| | | | | | | | | | ||
| | | 91 | 70 | 3.3 | 0.197 | 48 | 28 | 6.9 | ||
| | | 98 | 63 | 8.8 | 48 | 28 | 12.4 | |||
| | | | | | | | | | ||
| | | | | | | | | | ||
| | | 57 | 43 | 7.5 | 0.511 | 27 | 19 | 9.0 | 0.145 | |
| | | 58 | 42 | 10.2 | 25 | 21 | 8.8 | 0.195 | ||
| | | | | | | | | | | |
| | | 58 | 42 | 4.1 | 30 | 19 | 3.6 | 0.106 | ||
| | | 62 | 38 | 9.2 | 31 | 18 | 10.0 | 0.130 | ||
| | | | | | | | | |||
| | | | | | | | | | ||
| | | 90 | 60 | 8.5 | 0.101 | 48 | 29 | 7.6 | ||
| | | 88 | 62 | 7.6 | 44 | 33 | 10.0 | 0.204 | ||
| | | | | | | | | | ||
| | | 25 | 25 | −1.1 | 0.527 | 9 | 9 | −1.1 | 0.879 | |
| 32 | 18 | 16.7 | 0.069 | 12 | 6 | 15.9 | ||||
a Wilcoxon rank sum tests for pair-wise comparisons between MFIs for CS2 and MOZ2 at delivery and postpartum.
n>0 indicates the number of women with IgG levels higher at postpartum than at delivery and n<0 the number of women with IgG levels lower at postpartum than at delivery.
Difference (%) denotes the median difference in IgG levels between postpartum and delivery samples expressed in % of levels at delivery.
PG, primigravidae; SG, secundigravidae; MG, multigravidae; IPTp, intermittent preventive treatment in pregnancy; SP, sulphadoxine-pyrimethamine.
Analysis including all women and only those without infection were stratified by parity, postpartum period, HIV status and IPTp administration.